The proteolytic activity in inflammatory bowel disease: insight from gut microbiota.

Autor: Hou JJ; Department of Gastroenterology, Shaoxing People's Hospital, Shaoxing, PR China., Ding L; Department of Gastroenterology, Shaoxing People's Hospital, Shaoxing, PR China., Yang T; Department of Gastroenterology, Shaoxing People's Hospital, Shaoxing, PR China., Yang YF; Department of Gastroenterology, Shaoxing People's Hospital, Shaoxing, PR China., Jin YP; Department of Gastroenterology, Shaoxing People's Hospital, Shaoxing, PR China., Zhang XP; Department of Gastroenterology, Shaoxing People's Hospital, Shaoxing, PR China., Ma AH; Department of Gastroenterology, Shaoxing People's Hospital, Shaoxing, PR China., Qin YH; Department of Gastroenterology, Shaoxing People's Hospital, Shaoxing, PR China. Electronic address: qinsweet@sina.com.
Jazyk: angličtina
Zdroj: Microbial pathogenesis [Microb Pathog] 2024 Mar; Vol. 188, pp. 106560. Date of Electronic Publication: 2024 Jan 23.
DOI: 10.1016/j.micpath.2024.106560
Abstrakt: Inflammatory bowel disease (IBD) is a chronic, recurrent inflammatory disease caused by the destruction of the intestinal mucosal epithelium that affects a growing number of people worldwide. Although the etiology of IBD is complex and still elucidated, the role of dysbiosis and dysregulated proteolysis is well recognized. Various studies observed altered composition and diversity of gut microbiota, as well as increased proteolytic activity (PA) in serum, plasma, colonic mucosa, and fecal supernatant of IBD compared to healthy individuals. The imbalance of intestinal microecology and intestinal protein hydrolysis were gradually considered to be closely related to IBD. Notably, the pivotal role of intestinal microbiota in maintaining proteolytic balance received increasing attention. In summary, we have speculated a mesmerizing story, regarding the hidden role of PA and microbiota-derived PA hidden in IBD. Most importantly, we provided the diagnosis and therapeutic targets for IBD as well as the formulation of new treatment strategies for other digestive diseases and protease-related diseases.
Competing Interests: Declaration of competing interest Their authors declare that there are no conflicts of interest.
(Copyright © 2024. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: